-
The effects of 17α-estradiol treatment on endocrine system revealed by single-nucleus transcriptomic sequencing of hypothalamus
25 Sep 2025 19:27 GMT
… findings, 17α-estradiol treatment significantly decreased serum estradiol … treatment induces a pronounced stressed phenotype in Gnrh … neurons alongside elevated Gnrh secretion … -term 17α-estradiol treatment markedly alleviates the stressed …
-
Advances of Drug-Loaded Microsphere Technology for Targeted Immunotherapy Against Prostate Cancer
19 Sep 2025 16:43 GMT
… where it resists conventional treatments. Microcatheter-assisted drug-loaded microspheres have … -adsorbed drugs are rapidly released, quickly inhibiting pituitary GnRH receptors and … well as collaboration across clinical medicine, data science, and policy …
-
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
18 Sep 2025 11:56 GMT
… 9162
adjokovic@medicspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. … novel, non-invasive treatment for basal cell skin … 's flagship drug candidate is Teverelix trifluoroacetate … -releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which …
-
How Does Cancer Treatment Affect Menopause and Fertility?
11 Sep 2025 21:01 GMT
… . Elizabeth Sakach, breast medical oncologist at Winship Cancer … How do different cancer treatments, such as chemotherapy, … premature menopause during cancer treatment, such as fertility … function suppression, such as GnRH agonists like Lupron (leuprolide …
-
Gonadotropin-Releasing Hormone (GnRH) Agonists & Antagonists Drugs Market Report 2025: Trends, Drivers & Forecasts
21 Aug 2025 13:16 GMT
… for gonadotropin-releasing hormone (GnRH) agonists and antagonists medication is … monitoring reproductive treatments, advancements in … Gonadotropin-Releasing Hormone (GnRH) Agonists And Antagonists Drugs Market Growth
The gonadotropin-releasing hormone (gnrh …
-
Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Set to Reach $2.2 Billion by 2029
21 Aug 2025 13:16 GMT
… emphasis on minimally invasive treatment modalities, increasing governmental backing … of oncology drugs.
The market size for gonadotropin-releasing hormone (GnRH) receptor antagonists … for personalized and targeted medications, growing demand in developing …
-
Medicus Pharma Ltd. (NASDAQ: MDCX) Builds Momentum With Antev Acquisition And Pipeline Progress
05 Sep 2025 17:07 GMT
… Teverelix, a next-generation GnRH antagonist.
The acquisition could … disease.
Following the acquisition, Medicus moved quickly to reinforce … strategic depth to our drug development pipeline but also … loaded with doxorubicin to treat basal cell carcinoma. The …
-
Uterine Fibroids Treatment Market to Hit $26.58 Billion by 2031 | 11.8% CAGR Driven by Minimally Invasive Surgeries
28 Aug 2025 13:00 GMT
… minimally invasive techniques. Pharmaceutical treatments such as gonadotropin-releasing hormone (GnRH) antagonists and selective progesterone … 30–50, and investments in medical technology. The UK, Germany, and …
-
Investigating the Therapeutic Effects of Bushen Huoxue Formula Combined with Aerobic Exercise on Reproductive Function in Obese Polycystic Ovary Syndrome: An Experimental Study Based on the Integration of Sports and Medicine
27 Aug 2025 11:56 GMT
… foundation for treating obese PCOS through traditional Chinese medicine (TCM … exercise and medical care, utilizing medical expertise and … Following completion of the drug and exercise interventions … such as short-course GnRH antagonist protocols, metformin …
About
© 1995-2025